These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19469259)

  • 1. [Microbiol landscape and production of beta-lactamases with extended spectrum activity in patients with urinary tract infection].
    Zhevlakova IuA; Zakharova GV; Khokhlova OI; Ust'iantseva IM
    Klin Med (Mosk); 2009; 87(3):56-9. PubMed ID: 19469259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 3. Risks of extended-spectrum beta-lactamases.
    BMJ Group
    Drug Ther Bull; 2008 Mar; 46(3):21-4. PubMed ID: 18337463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new beta-lactamases.
    Jacoby GA; Munoz-Price LS
    N Engl J Med; 2005 Jan; 352(4):380-91. PubMed ID: 15673804
    [No Abstract]   [Full Text] [Related]  

  • 6. [Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
    Barcelona L; Marín M; Stamboulian D
    Medicina (B Aires); 2008; 68(1):65-74. PubMed ID: 18416324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Lactam resistance and beta-lactamases in bacteria of animal origin.
    Li XZ; Mehrotra M; Ghimire S; Adewoye L
    Vet Microbiol; 2007 Apr; 121(3-4):197-214. PubMed ID: 17306475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report.
    Berg ML; Crank CW; Philbrick AH; Hayden MK
    Ann Pharmacother; 2008 Feb; 42(2):207-12. PubMed ID: 18230703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
    Teng CP; Chen HH; Chan J; Lye DC
    Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of co-expression of newer beta-lactamases (ESBLs, Amp-C-beta-lactamases, and metallo-beta-lactamases) in gram-negative bacilli.
    Chatterjee SS; Karmacharya R; Madhup SK; Gautam V; Das A; Ray P
    Indian J Med Microbiol; 2010; 28(3):267-8. PubMed ID: 20644325
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections.
    Suárez CJ; Lolans K; Villegas MV; Quinn JP
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):915-22. PubMed ID: 16307504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of sensitivity to antibiotics of microorganisms isolated from children with urinary tract infections].
    Cisowska A; Lewczyk E; Korzekwa K; Wojnicz D; Jankowski S; Doroszkiewicz W
    Pol Merkur Lekarski; 2003 Apr; 14(82):322-6. PubMed ID: 12868193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
    Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
    J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of extended-spectrum beta-lactamases in South America.
    Villegas MV; Kattan JN; Quinteros MG; Casellas JM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():154-8. PubMed ID: 18154539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of bacterial beta-lactamase production in the treatment of urinary tract infections with oral beta-lactam-antibiotics].
    Naber K; Ahrens T; Zimmermann W; Puppel H; Schultheis H; Maly V
    Urologe A; 1982 Jul; 21(4):225-8. PubMed ID: 6982557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance to fluoroquinolone among Klebsiella spp strains producing extended-spectrum betalactamases isolated from urine].
    Tlamçani Z; Ellaia K; Benomar A; Kabbaj H; Alaoui A; Seffar M
    Ann Biol Clin (Paris); 2009; 67(5):553-6. PubMed ID: 19789127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.